{"id":14907,"date":"2021-05-05T17:03:01","date_gmt":"2021-05-05T15:03:01","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?page_id=14907"},"modified":"2024-01-05T14:26:48","modified_gmt":"2024-01-05T13:26:48","slug":"ash-2020","status":"publish","type":"page","link":"https:\/\/www.hematostat.net\/en\/ash-2020\/","title":{"rendered":"ASH 2020"},"content":{"rendered":"
<\/span><\/div>

[3d-flip-book mode=”link-lightbox” id=”14910″ lightbox=”dark”]Voir le num\u00e9ro complet[\/3d-flip-book]<\/strong><\/p>\n<\/div><\/div><\/div>

Avant-propos<\/p>\n

LEUC\u00c9MIE LYMPHO\u00cfDE CHRONIQUE (LLC)<\/span><\/h3>\n

Ibrutinib en 1\u00e8re ligne apr\u00e8s 12 mois d\u2019association avec le\u00a0v\u00e9n\u00e9toclax : stop ou encore ?\u00a0Luc-Matthieu FORNECKER, Vincent L\u00c9VY
\n<\/strong>Traitements de dur\u00e9e fixe ou traitements continus en 1\u00e8re ligne\u00a0dans la leuc\u00e9mie lympho\u00efde chronique : comment choisir ?\u00a0Luc-Matthieu FORNECKER, Vincent L\u00c9VY
\n<\/strong>Arr\u00eat ou diminution de dose de l\u2019ibrutinib : qu\u2019en est-il en\u00a0pratique ?\u00a0Luc-Matthieu FORNECKER, Vincent L\u00c9VY
\n<\/strong>Les alt\u00e9rations de la voie p53 ont-elles encore un impact\u00a0pronostique en 1\u00e8re ligne sous traitement par ibrutinib ?\u00a0Luc-Matthieu FORNECKER, Vincent L\u00c9VY<\/strong><\/p>\n

SYNDROMES MY\u00c9LODYSPLASIQUES<\/span><\/h3>\n

MDS de haut risque : la greffe pour tous !\u00a0Emmanuel GYAN, J\u00e9r\u00f4me LAMBERT<\/strong>
\nEssai DACOTA dans la LMMC : la difficile conqu\u00eate de la survie\u00a0Emmanuel GYAN, J\u00e9r\u00f4me LAMBERT<\/strong>
\nTraitements hypom\u00e9thylants dans les SMD de haut risque : la\u00a0r\u00e9ponse dans la machine ?\u00a0Emmanuel GYAN, J\u00e9r\u00f4me LAMBERT<\/strong>
\nL\u00e9nalidomide dans les MDS avec del(5q) : le plus t\u00f4t c\u2019est le\u00a0mieux !\u00a0Emmanuel GYAN, J\u00e9r\u00f4me LAMBERT<\/strong><\/p>\n

LEUC\u00c9MIES AIGU\u00cbS<\/span><\/h3>\n

Une simple ou une double pour votre induction ?\u00a0\u00c9tienne LENGLINE, J\u00e9r\u00f4me LAMBERT<\/strong>
\nL\u2019enasidenib \u00e0 la recherche de synergie\u00a0\u00c9tienne LENGLINE, J\u00e9r\u00f4me LAMBERT<\/strong>
\nUn traitement anti-CD19 peut en cacher un autre\u00a0\u00c9tienne LENGLINE, J\u00e9r\u00f4me LAMBERT<\/strong>
\nLe laboratoire de cytologie bient\u00f4t remplac\u00e9 par des robots ?\u00a0\u00c9tienne LENGLINE, J\u00e9r\u00f4me LAMBERT<\/strong><\/b><\/p>\n

MY\u00c9LOME MULTIPLE<\/span><\/h3>\n

GRIFFIN : une nouvelle quadruplette en induction\u00a0Titouan CAZAUBIEL, Aurore PERROT, Audrey LAVENU
\n<\/strong>Autogreffe dans le my\u00e9lome : la Vieille Dame toujours d\u2019actualit\u00e9\u00a0Titouan CAZAUBIEL, Aurore PERROT, Audrey LAVENU
\n<\/strong>EMN02\/HO95 : consolidons la premi\u00e8re ligne !\u00a0Titouan CAZAUBIEL, Aurore PERROT, Audrey LAVENU
\n<\/strong>Isatuximab-Carfilzomib-Dexam\u00e9thasone : un potentiel nouveau standard\u00a0Titouan CAZAUBIEL, Aurore PERROT, Audrey LAVENU<\/strong><\/p>\n

LES LYMPHOMES<\/span><\/h3>\n

Le pouvoir pr\u00e9dictif de la MRD dans le manteau\u00a0J\u00e9r\u00f4me PAILLASSA, Audrey LAVENU<\/strong>
\nPassion tricho\u00a0J\u00e9r\u00f4me PAILLASSA, Audrey LAVENU<\/strong>
\nConfirmation des b\u00e9n\u00e9fices d\u2019une strat\u00e9gie guid\u00e9e par le TEP-scanner dans le Hodgkin\u00a0J\u00e9r\u00f4me PAILLASSA, Audrey LAVENU
\n<\/strong>Lymphomes folliculaires et de la zone marginale : d\u00e9sormais les CAR T en main !\u00a0J\u00e9r\u00f4me PAILLASSA, Audrey LAVENU
\n<\/strong>La mode IPI\u00a0J\u00e9r\u00f4me PAILLASSA, Audrey LAVENU<\/strong><\/p>\n

FOCUS STATISTIQUES G\u00c9N\u00c9RAUX<\/span><\/h3>\n

Traitement a sup\u00e9rieur \u00e0 b, traitement a non inf\u00e9rieur \u00e0 b, mais de quoi s\u2019agit-il ?\u00a0Audrey LAVENU<\/strong>
\nUn nouveau score de risque, comment le valider ?\u00a0Audrey LAVENU<\/strong>
\nTest d\u2019hypoth\u00e8se \u2013 hypoth\u00e8ses nulle-hypoth\u00e8se\u00a0Vincent L\u00c9VY<\/strong><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-14907","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/pages\/14907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=14907"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/pages\/14907\/revisions"}],"predecessor-version":[{"id":17316,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/pages\/14907\/revisions\/17316"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=14907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}